Sanxin Medtec released its performance for the first three quarters, with a net profit attributable to the parent company of 185 million yuan, an increase of 10.16%

According to the Zhitong Finance APP, Sanxin Medtec released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.168 billion yuan, a year-on-year increase of 7.88%. The net profit attributable to shareholders of the listed company was 185 million yuan, a year-on-year increase of 10.16%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 167 million yuan, a year-on-year increase of 10.09%. The basic earnings per share were 0.3573 yuan

Western Securities: The time for domestic substitution of blood dialysis is right; optimistic about major products, diversification, and overseas expansion

Western Securities released a research report indicating that the market for blood dialysis medical devices in China is steadily growing, with a CAGR of 5.67% from 2019 to 2023, and is expected to reach 21.52% from 2023 to 2027. With the increasing number of ESRD patients and the improvement in residents' medical payment capabilities, the demand for dialysis continues to grow. The acceleration of domestic substitution, the recovery of bidding, and the release of overseas potential are characteristics of the industry. The market size for blood dialysis machines, devices, and tubing is expected to grow significantly in the coming years

Sanxin Medtec: Four products obtained EU MDR certification

Sanxin Medtec recently obtained the EU Medical Device Regulation (MDR) certification issued by the German Rhine TÜV Group, covering four products including disposable sterile injection needles, retractable self-destructing sterile syringes, precision filter infusion sets, and infusion sets. This certification indicates that the company has established a quality management system in compliance with EU MDR regulations, marking that the products meet the latest regulatory requirements, which will aid in promotion and sales in the EU and other countries that recognize MDR certification, enhancing global market competitiveness

Sanxin Medtec: The holding subsidiary has changed the medical device production license

Sanxin Medtec announced that its holding subsidiary Chengdu Weili Sheng Biological Technology Co., Ltd. has changed the production scope of its medical device manufacturing license to adapt to the adjustments of the "Medical Device Classification Catalog." The new license was reissued by the Sichuan Provincial Drug Administration, with the number Chuan Yao Jian Xie Sheng Chan Xu 20160053, covering Class II and Class III blood purification and peritoneal dialysis equipment, with a validity period from December 10, 2020, to December 9, 2025. This change has no significant impact on the company's production and operations

The medical device sector has risen again, with SINOMED, David Medical, MEDLANDER, and Sanxin Medtec increasing by over 10%, while Sanyou Medical and MTM also followed suit